Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Achieving optimal outcomes in chronic lymphocytic leukaemia.

T J Hamblin1

  • 1Department of Haematology, Royal Bournemouth Hospital, England. terjoha@aol.com

Drugs
|May 23, 2001
PubMed
Summary

Chronic lymphocytic leukaemia (CLL) is a common cancer in older adults, often diagnosed incidentally. While some patients require no treatment, others may progress and need therapies like chlorambucil or fludarabine.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Problems of Anticoagulant Control-II, Which Test?

Bristol medico-chirurgical journal (1963)·2017
Same author

CLL Trials in the United Kingdom the Medical Research Council CLL Trials 1, 2 and 3.

Leukemia & lymphoma·2016
Same author

Reading for Pleasure: More worlds per pound.

British medical journal·2010
Same author

The immunodeficiency of chronic lymphocytic leukaemia.

British medical bulletin·2008
Same author

Chronic lymphocytic leukaemia.

Lancet (London, England)·2008
Same author

Chronic lymphocytic leukaemia: clinical translations of biological features.

Current topics in microbiology and immunology·2005

Area of Science:

  • Hematology
  • Oncology

Background:

  • Chronic lymphocytic leukaemia (CLL) is a lymphoid malignancy primarily affecting older adults.
  • Diagnosis is typically incidental via lymphocytosis, requiring differentiation from other small B-cell lymphomas using specific lymphocyte markers.
  • CLL staging is based on lymphadenopathy, splenomegaly, and bone marrow suppression, with approximately 50% of patients having early-stage disease and a normal life expectancy without treatment.

Purpose of the Study:

  • To provide an overview of Chronic lymphocytic leukaemia (CLL) diagnosis, staging, and management.
  • To discuss prognostic factors and treatment strategies for CLL, including first-line therapies, relapsed/refractory disease, and novel approaches.
  • To highlight the potential for curative intent treatments in younger patients and the role of stem cell transplantation and immunotherapy.

Main Methods:

  • Review of diagnostic criteria for CLL, including immunophenotyping (sparse surface immunoglobulin, CD5+, CD19+, CD23+, CD79b-, FMC7-).
  • Description of staging systems based on clinical and hematologic features.
  • Analysis of treatment options, including chlorambucil, fludarabine, cladribine, combination chemotherapy, and newer agents, as well as stem cell transplantation and immunotherapy.

Main Results:

  • Most CLL patients are diagnosed at an early stage, with 50% never progressing and having a normal life expectancy.
  • Progression of CLL can lead to increasing white cell count, lymphadenopathy, splenomegaly, anemia, thrombocytopenia, and complications like autoimmune cytopenias and secondary malignancies.
  • Chlorambucil remains a first-line treatment, with fludarabine potentially more effective but significantly more expensive. Relapsed or refractory disease management involves various treatment options, including clinical trials.

Conclusions:

  • CLL management requires careful staging and risk stratification, with observation being appropriate for early-stage, non-progressing patients.
  • Treatment decisions for CLL depend on disease stage, progression, and patient factors, with established therapies and emerging options available.
  • Curative intent strategies, including stem cell transplantation and immunotherapy, are being explored for younger patients or those with refractory disease, offering hope for improved outcomes.

Related Experiment Videos